Aquestive Therapeutics, Inc.
AQSTHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The $516.9M market capitalization puts AQST squarely in small-cap range for its industry. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
Market Cap
$516.9M
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
-9.16
EPS (TTM)
$-0.61
EPS (Fwd)
$-0.45
ROE
—
ROA
-28.7%
Cash
$110.7M
Total Debt
$43.6M
Free CF
-$25.7M
52W Change
-1.9%
Annual Financials
Cash vs Debt
Aquestive Therapeutics, Inc. holds $110.7M in cash against $43.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$25.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $47.7M (2022) to $44.5M (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aquestive Therapeutics, Inc.'s trajectory.